News

Eli Lilly: Another Not-To-Miss Dip
Eli Lilly's stock dipped after drug trial results, but strong Q2 2025 earnings and market position make it a strong buy. Read ...
Lilly pill cuts body weight by 12.4% in trial, lagging Novo's Wegovy injection
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage ...
Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
Lilly raises full-year earnings forecasts on surging demand for weight-loss drug
Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...
Benzinga.com1d
Eli Lilly's Orforglipron Data Is Not Disastrous: Analyst
Orforglipron cut weight by 12.4% vs. 0.9% with placebo, below 15% expectations. BofA lowered Eli Lilly's price forecast to ...
S&P 500 eases with Eli Lilly; Nasdaq manages record closing high
The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, ...